Genentech updates on Cabilly patent peexamination

Genentech, Inc. has announced today that the U.S. Patent and Trademark Office issued a final Office action in its reexamination of the Cabilly, et al. U.S. Patent No. 6,331,415 ('415 patent) and rejected the patentability of the claims of the '415 patent.

Genentech plans to respond to the final Office action within the next several months and, if necessary, appeal the decision through all appropriate means of review within the Patent Office and the courts.

The U.S. Patent Office has made a copy of the final Office action available to the public on its website.

The '415 patent remains valid and enforceable through the appeals process. The company estimates that the entire appeals process may take approximately one to two years, or longer.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.